by Raynovich Rod | Oct 25, 2020 | 2009-2017 Life Science Portfolios, 2020 Rayno Biopharmaceuticals Portfolio, Macro
Update-1 10/26…S&P takes a 1.86% Hit on Lack of Stimulus and a Spike in Cases First look at winners among our holdings: ABT up 1.13% post last week’s earnings, AZN up 2.06% on resumed vaccine trials, BDX up 0.72%, OSUR up 6.77% a rapid COVID test...
by Raynovich Rod | Oct 19, 2020 | 2009-2017 Life Science Portfolios, 2020 Rayno Biopharmaceuticals Portfolio
Update-3 10/21 11a EDT Another day with a brisk sell-off in momentum stocks. Coronavirus plays hit hard: BNTX, QDEL, NVAX, OSUR etc. Is this sentiment shift from lack of stimulus or just election anxiety? After the close: CRISPR Therapeutics (CRSP) down 12.95% to...
by Raynovich Rod | Oct 7, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/15 1;20P… Both the IBB and XBI are stalled at the current 2020 double top. Our new picks are holding OSUR at $14.65, PACB $14.42 and VIR at $42. 10/16 11 a BioNTech (BNTX) and Pfizer emerging as vaccine leaders.Data coming soon. ==============...
by Raynovich Rod | Sep 28, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/6…Apparently a Momentum Market needs constant feeding. Politics are in the forefront. And the COIVID pandemic lingers. Small caps did better IWM down only 0.25%, IJR flat. Large cap biotech was not a place to hide either. Coronavirus winners today...
by Raynovich Rod | Sep 21, 2020 | Biopharmaceuticals
Update-3…2:20p Coronavirus Stocks on the Move-Rally Time for Traders In typical fashion in a momentum market when NASDAQ rallies biotech moves up.Big movers today (see chart below) are: pure play vaccine stocks BNTX, INO, MRNA, NVAX and Dx is strong as well...
by Raynovich Rod | Sep 13, 2020 | Biopharmaceuticals
Update-3 Coronavirus stocks are back led by testing boom and near term clinical news on CPOVID vaccine. Keep in mind it was a “triple witching” day.Here is a look-back to where we were with Coronavirus stocks on June 28. All pure play testing stocks are up...
by Raynovich Rod | Sep 7, 2020 | 2020 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 Choppy Day but Investors coming Back to Healthcare and Biopharma. IBB and XLV up a tad. XBI flat. Rotation out of high flying tech into healthcare and industrials. Large caps winners : AMGN and GILD then AZN,RHHBY,MRK looking for large caps that have Dx and...
by Raynovich Rod | Aug 30, 2020 | Biopharmaceuticals, coronavirus vaccine, vaccines
Update-2 Downdraft surprises investors-momentum shift ! We have been talking about this for weeks, How much higher can the FAANG names go? The momentum is unprecedented. Bifurcated market. Well today the sell-off was in full swing with broad damage across the...
by Raynovich Rod | Aug 18, 2020 | 2020 Rayno Biopharmaceuticals Portfolio, 2020 Rayno Tools and Diagnostics Portfolio
We took profits on many longs and shorts in the coronavirus sector so I will need to look at new trades for Q4. Our small longs for now are ABT, AZT, GNMK, GILD, MRNA, MRK, OSUR and TDOC. However We are also long many large caps in addition to above: ABBV, BMY, JNJ,...
by Raynovich Rod | Aug 10, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, Vaccines
August 15..Update -3…Momentum slows to a walk but XBI holds the $110 handle. XLV flat at $107 level, IBB down 0.86% to $133.30. Coronavirus stocks still within 10% of 52 week highs: HOLX,REGN; weak 2020 momentum: CEMI, INO. Vaccine stock leaders: NVAX, MRNA. Gov...
